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the cytotoxicity marker lactate dehydrogenase (LDH) com-
pared to controls. Quantitative real-time PCR analyses con-
firmed the early deregulation of miR-187-3p, miR-182-5p, 
miR-486-3p, miR-486-5p, miR-34a-3p, miR-4423-3p, 
miR-34c-3p, miR-34c-5p and miR-1303, and also the pro-
longed up-regulation of miR-182-5p, miR-4423-3p and 
miR-34c-5p. Thus, we identified and validated miRNAs 
showing differential DOX-responsive expression before the 
occurrence of cytotoxicity markers such as LDH, and these 
miRNAs also demonstrated the significant involvement in 
heart failure in patients and animal models. These results 
suggest that the DOX-induced deregulated miRNAs in 
human CMs may be used as early sensitive cardiotoxicity 
biomarkers for screening potential drugs and environmen-
tal cardiotoxicants with a similar mechanism of action.
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Introduction
Irreversible cardiac injury is a most serious side effect 
associated with many known anti-cancer drugs and other 
therapeutic drugs, putting patients’ lives at risk. Further-
more, over the last two decades, the pharmaceutical indus-
try has been struggling with the costly withdrawals of new 
drug candidates in late-stage clinical trials. Thus, one of 
the major tasks of pharmaceutical companies is to predict 
the cardiotoxic side effects of new drug candidates early in 
non-clinical phases of drug development. Moreover, it has 
been recognized since long time that environmental toxi-
cants and pollutants may induce cardiotoxicity in animals 
and humans (Simkhovich et al. 2009). Several preclinical 
models have been developed to understand doxorubicin 
Abstract An in depth investigation at the genomic level 
is needed to identify early human-relevant cardiotoxicity 
biomarkers that are induced by drugs and environmental 
toxicants. The main objective of this study was to inves-
tigate the role of microRNAs (miRNAs) as cardiotoxic-
ity biomarkers using human-induced pluripotent stem cell 
(hiPSC)-derived cardiomyocytes (CMs) that were exposed 
to doxorubicin (DOX) as a “gold standard” cardiotoxicant. 
hiPSC-CMs were exposed to 156 nM DOX for 2 days or 
for 6 days of repeated exposure, followed by drug wash-
out and incubation in drug-free culture medium up to day 
14 after the onset of exposure. The induced miRNAs were 
profiled using miRNA microarrays, and the analysis of the 
data was performed using the miRWalk 2.0 and DAVID 
bioinformatics tools. DOX induced early deregulation of 
14 miRNAs (10 up-regulated and 4 down-regulated) and 
persistent up-regulation of 5 miRNAs during drug washout. 
Computational miRNA gene target predictions suggested 
that several DOX-responsive miRNAs might regulate the 
mRNA expression of genes involved in cardiac contrac-
tile function. The hiPSC-CMs exposed to DOX in a range 
from 39 to 156 nM did not show a significant release of 
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(DOX)-induced early and chronic cardiotoxicity (AbdelAl-
eem et al. 1997; Banco et al. 2011; Desai et al. 2013; Hrelia 
et al. 2002; Jaenke 1974; Tokarska-Schlattner et al. 2005). 
Importantly, all of these established models are non-human 
in origin. Due to an inter-species variation in physiology, 
assays using these established models cannot reliably pre-
dict the cardiotoxic effects of new drugs in humans. How-
ever, current studies have demonstrated that in vitro use of 
human embryonic stem cell (hESC)- or human-induced 
pluripotent stem cell (hiPSC)-derived cardiomyocytes can 
be beneficial for preclinical safety assessment.
Currently applied diagnostic techniques [ecocardio-
graphic left ventricular ejection fraction (LVEF), radionu-
clide angiography and endomyocardial biopsy] for assess-
ing drug-induced cardiac injury have many shortcomings, 
including sensitivity, invasiveness and high cost. In preclin-
ical and clinical phase studies, troponins (cTnT and cTnI) 
have been used as highly sensitive plasma biomarkers for 
detecting DOX-induced cardiac damage (Herman et al. 
1998, 1999; Lipshultz et al. 2012; O’Brien 2006; O’Brien 
et al. 2006; Shahzadi et al. 2014). However, troponins and 
many other cardiac biomarkers show increased plasma lev-
els only after heart tissue damage and also have a limited 
half-life (Tonomura et al. 2009; Walker 2006). Consider-
ing the disadvantages of current biomarkers, there is an 
urgent need to identify stable, highly sensitive and nonin-
vasive genomic biomarkers to predict early events of drug-
induced cardiac damage.
Among anthracyclines, DOX is a highly effective anti-
cancer drug prescribed for the treatment of a variety of 
cancer types, including solid tumours and haematologic 
malignancies in both adults and children. Despite its 
beneficial therapeutic effects, the long-term clinical use 
of DOX is limited, due to its cumulative dose-depend-
ent cardiotoxicity (Singal and Iliskovic 1998). A recent 
meta-analysis demonstrates that anthracycline treatment 
increased the risk of cardiac death by 4.94-fold com-
pared to non-anthracycline treatments (Smith et al. 2010). 
The acute adverse effects of DOX occur within or after 
2–3 days of administration and are manifested by car-
diac arrhythmias and acute heart failure. The chronic side 
effects of DOX are largely dose-dependent. A patient 
may develop dilated cardiomyopathy shortly after DOX 
treatment termination, or dilated cardiomyopathy may 
occur even 10–15 years after the termination of chemo-
therapy. Acute and chronic DOX administration may lead 
to cardiac dysfunction, cardiomyopathy and ultimately 
to heart failure and death (Chatterjee et al. 2010; Wal-
lace 2003; Yeh et al. 2004). DOX is a well-characterized 
cardiotoxicant of the anthracycline family, but the exact 
mechanisms of DOX-induced cardiotoxicity are not fully 
understood. Nevertheless, DOX can be applied as a sub-
stance to identify human-relevant genomic biomarkers for 
potential cardiotoxic drugs and environmental factors that 
induce cardiotoxicity (Chaudhari et al. 2015).
Small non-coding RNAs that are approximately 22 
nucleotides long are known as microRNAs (miRNAs) that 
regulate gene expression by targeting messenger RNAs 
(mRNAs) by binding to complementary regions of tran-
scripts to inhibit their translation and/or promote mRNA 
degradation (Ambros 2004; Bartel 2004). In particular, 
miRNAs are significantly involved in heart development, 
physiology and pathogenesis (Latronico and Condorelli 
2009; Rao et al. 2009; Small et al. 2010a). These functions 
make miRNAs an attractive target for identifying sensi-
tive biomarkers of cardiovascular diseases (Bernardo et al. 
2012; D’Alessandra et al. 2010; Matsumoto et al. 2013).
Here, for the first time, we identify set of miRNAs as tox-
icity signatures of DOX in hiPSC-cardiomyocytes (CMs). In 
the present study, we aimed to identify early and prolonged 
differential expression of miRNAs in response to DOX expo-
sure in hiPSC-CMs by profiling global miRNA levels. Our 
miRNA microarray results identified 14 early DOX-respon-
sive miRNAs (10 up-regulated and 4 down-regulated), and 
five miRNAs that are persistently up-regulated during drug 
washout. DOX-deregulated miRNAs and their in silico pre-
dicted gene targets are associated with intact cardiac func-
tion and cardiac diseases. Our results demonstrate that early 
and/or prolonged deregulated miRNAs are promising broad 
biomarkers of cardiotoxicity that also provide information 
regarding the early events of cardiac damage.
Materials and methods
Cardiomyocyte cell culture
All experiments were performed using iCell Cardiomyocytes® 
(Cellular Dynamics International, Madison, WI, USA) derived 
from hiPSCs. A 98 % pure population of cardiomyocytes was 
supplied in a cryopreserved single-cell suspension. The cardi-
omyocytes were a mixture of electrically active atrial-, nodal- 
and ventricle-like myocytes. Cryopreserved cardiomyocytes 
were thawed and plated on fibronectin-coated (5 µg/cm2, 
2 h at 37 °C) (Sigma-Aldrich, Steinheim, Germany) 6-well 
plates and 96-well plates using iCell Cardiomyocytes Plating 
Medium (iCell-PM) (Cellular Dynamics International, Madi-
son, WI, USA). Two days post-plating, cells were cultured 
in iCell Cardiomyocytes Maintenance Medium (iCell-MM) 
(Cellular Dynamics International, Madison, WI, USA), with 
fresh media changed every 2 days.
Test compound
A 10 mM stock solution (in DMSO) of DOX was pur-
chased from Selleck chemicals. The stock solution was 
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dispensed into small volume aliquots and stored at −80 °C. 
The drug dilutions were performed in iCell-MM at room 
temperature prior to each drug exposure.
DOX exposure and cell sample collection 
for microarray studies
A schematic representation of the experimental design is 
shown in Fig. 1. Briefly, the iCell cardiomyocytes were 
cultured in a 6-well plate at a density of 0.4 × 106 cells 
per well. Four days post-plating, the synchronously beating 
cardiomyocytes were incubated with DOX at 156 nM for 
a 2-day exposure period (DOX-Day2) or three consecutive 
exposure periods of DOX for 6 days (DOX-Day6) (DOX 
supplemental media was refreshed every 48 h). Following 
DOX exposure for a 2-day washout (DOX-Day2WO) or a 
6-day washout (DOX-Day6WO), cardiomyocytes were fur-
ther cultivated in DOX-free iCell-MM until day 14 (from 
the start of the drug exposure). Non-treated control cells 
were cultured for 6 days in iCell-MM with DMSO as the 
solvent. The culture medium was refreshed every 2 days. 
The control, DOX-exposed and drug washout cell sam-
ples were harvested on day 2, 6 and 14, respectively, using 
QIAzol lysis reagent (Qiagen, Hilden, Germany). Total 
RNA, including non-coding miRNAs, were extracted from 
harvested cell samples and used for miRNA microarray 
hybridization and real-time PCR studies.
Total RNA extraction
The total RNA, including non-coding miRNAs, were iso-
lated from control, DOX-exposed and drug washout cardio-
myocytes using the miRNeasy Mini Kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s instructions. 
Concentration and purity of the isolated RNA was evalu-
ated using a Nanodrop ND-1000 spectrophotometer (ND-
1000, Thermo Fisher, Langenselbold, Germany). RNA 
integrity was confirmed using the Experion™ automated 
electrophoresis system (Bio-Rad, Munich, Germany).
miRNA microarray labelling and hybridization
The FlashTag Biotin HSR RNA labelling Kit (Affyme-
trix, High Wycombe, United Kingdom) was used to label 
500 ng of total RNA. The biotin labelled samples were 
hybridized to GeneChip miRNA 3.0 arrays (Affymetrix, 
High Wycombe, United Kingdom) using a hybridization 
cocktail. Microarray hybridization was performed in an 
Affymetrix GeneChip Hybridization Oven-645 for 16 h 
at 48 °C and 60 rpm. Hybridized arrays were washed and 
stained using the GeneChip HWS Kit (Affymetrix, High 
Wycombe, United Kingdom) and the fluidics station pro-
tocol (FS450_0002) on an Affymetrix GeneChip Fluid-
ics Station-450. The stained arrays were scanned with an 
Affymetrix GeneChip Scanner-3000-7G, and quality of 
the scanned arrays was evaluated using Affymetrix GCOS 
software. The generated raw data files were used for data 
analysis.
miRNA microarray data analysis
The miRNA expression data procured from the Gene-
Chip® miRNA 3.0 arrays were quantile normalized using 
the RMA approach with the Partek® Genomics Suite® soft-
ware, version 6.6 (Copyright Partek Inc., St. Louis, MO, 
USA). The probe sets for 5787 miRNAs specific to Homo 
Fig. 1  Experimental design for repeated drug exposure to hiPSC-
CMs. Synchronously beating cardiomyocytes were given a single 
DOX exposure for 2 days or repeated DOX exposure for 6 days (the 
DOX-supplemented culture media was refreshed every 2 days). Fol-
lowing single and repeated drug exposure, the cells were cultured in 
drug-free culture media until day 14 (after the onset of drug expo-
sure). During the drug washout, the culture medium was refreshed 
every 2 days. For microarray studies, cell samples were harvested on 
day 2, 6 and 14. This figure was reproduced from our previous report 
(Chaudhari et al. 2015)
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sapiens were selected further for statistical calculation. 
The differential expressions between groups were analysed 
for DOX-Day2 versus Control-Day2, DOX-Day6 versus 
Control-Day6, and DOX-Day2WO and DOX-Day6WO 
versus Control-Day14. Statistical calculations to deter-
mine significant genes were executed with the linear model 
implementation of the R Limma package followed by a 
Benjamini-Hochberg multiple test correction (1 % FDR). 
The miRNAs with a minimum fold change 1.8 and p value 
<0.05 were selected for further data analysis.
Prediction of miRNA‑gene targets
The gene target prediction of perturbed miRNAs was per-
formed using the miRWalk 2.0 database (Dweep et al. 
2011). Unlike currently available miRNA-gene target pre-
dictive tools, miRWalk 2.0 can identify putative miRNA 
binding sites not only in the 3′-UTR region but also in 
the promoter, the 5′-UTR and the CDS (amino acid cod-
ing sequence) regions of a gene. The miRWalk database 
is updated routinely and also provides information on 
validated miRNA binding sites in human genes. The pre-
dicted gene targets of the miRNAs were systematically 
compared and verified with our previously reported DOX 
transcriptomic data that contains differentially expressed 
genes (fold change of 2.0, FDR® p value <0.05) for DOX-
Day2, DOX-Day6, DOX-Day2WO and DOX-Day6WO 
groups (Chaudhari et al. 2015) (Fig. 2a). The predicted 
gene targets of the up-regulated miRNAs were verified 
with commonly down-regulated genes among the DOX-
Day2 and DOX-Day6 groups, while the predicted gene 
targets of down-regulated miRNAs were confirmed by 
comparison with the commonly up-regulated genes 
between the DOX-Day2 and DOX-Day6 groups (Fig. 2b). 
Similarly, the predicted gene targets of the persistently 
up-regulated miRNAs were verified with prolonged 
down-regulated genes (Fig. 2c). Verified gene targets from 
the transcriptome data were used for Gene ontology (GO) 
analysis. The GO enrichment and KEGG pathway analy-
ses were performed using the online Database for Anno-
tation, Visualization and Integrated Discovery (DAVID) 
programme (Dennis et al. 2003).
Quantitative real‑time PCR (qPCR)
Using 500 ng of total RNA, cDNA synthesis was per-
formed with the qScript™ microRNA cDNA Synthesis 
Kit (Quanta Biosciences, Gaithersburg, USA) following 
the manufacturer’s instructions. The cDNA was diluted 
fivefold with nuclease-free water, and 1 µl was used as a 
template for qPCR. The amplification of miRNA was per-
formed using the PerfeCTa® microRNA assay primer, 
the PerfeCTa® Universal PCR primer and the PerfeCTa® 
SYBR® Green SuperMix, Low ROX™ Kit (Quanta Bio-
sciences, Gaithersburg, USA) as per the manufacturer’s 
instructions. qPCR was carried out on an Applied Biosys-
tems 7500 FAST Real-Time PCR System. Relative miRNA 
levels were calculated using the ΔΔCt method, and RNU6 
was used as the miRNA PCR control.
Fig. 2  a Flow chart of the microarray data analysis used in this work. 
Differentially expressed miRNAs and their putative gene targets were 
verified with gene expression (mRNA) data subsequently the verified 
gene targets were used for the GO analysis. b, c Overlapping genes 
from the transcriptomic data matched with the miRNA gene targets 
predicted using miRWalk 2.0. Venn diagrams show that the predicted 
gene targets of the up-regulated miRNAs matched with the overlap-
ping down-regulated genes and vice versa. Confirmed gene targets 
used for GO analysis
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LDH leakage assay
Lactate dehydrogenase (LDH) is a widely used marker to 
evaluate the presence of damage and toxicity in cells and 
tissues. LDH is a cytosolic enzyme that is not normally 
discharged outside of the cell, but upon plasma mem-
brane damage of cells, LDH is released into the cell cul-
ture medium or blood. Measurement of extracellular LDH 
release into the culture medium can be used to assay cel-
lular toxicity. The iCell cardiomyocytes were seeded on a 
fibronectin-coated (5 µg/cm2, 2 h at 37 °C) 96-well plate at 
a cell density of 20 × 103 per well. On day 4 post-seeding, 
cardiomyocytes were exposed to DOX at different concen-
trations. After 48 h of exposure, extracellular LDH activity 
was measured using the Thermo Scientific™ Pierce™ LDH 
Cytotoxicity Assay Kit according to the manufacturer’s 
instructions. Absorbance was measured at 490 nm using the 
Softmax Pro M5e 96-well plate reader (Molecular Devices, 
Sunnyvale, CA, USA). LDH activity was expressed as fold 
change versus control samples.
Results
Repeated exposure to DOX‑induced cytotoxicity
Similar to our previous report (Chaudhari et al. 2015), 
repeated exposure to DOX induced significant cytotox-
icity at day 6 (DOX-Day6) compared to Control-Day6 
cardiomyocytes (Fig. 3a). This result is indicative of a 
decrease in cell viability and ultimately cardiac cell loss. 





Fig. 3  a Effect of DOX (156 nM) single and repeated exposure on 
cell viability. Cell images show that compared to controls, hiPSC-
CM viability neither changed during single DOX exposure (DOX-
Day2) nor during drug washout in DOX-Day2WO group. However, 
compared to controls, repeated exposure to DOX induced significant 
cytotoxicity and resulted in decreased cell viability in the DOX-Day6 
group. During drug washout, slightly more cell death was observed in 
the DOX-Day6WO group compared to the DOX-Day6 group. Scale 
bar indicates 50 µm. B, DOX-induced cytotoxicity was assessed 
by LDH leakage assay. The hiPSC-CMs were incubated with DOX 
for 48 h at a concentration range of 0.039–1.25 µM. The enzymatic 
activity was analysed for the cellular release of LDH into the culture 
media. The bar graph shows mean values of fold change compared to 
controls, and the error bars indicate the standard deviation (n = 4). 
***p value <0.001 versus control group
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cardiomyocytes (DOX-Day6WO), a slight, but not signifi-
cant, decrease in cell viability was observed compared to 
the DOX-Day6 group. A single exposure of DOX did not 
induce a significant level of cytotoxicity in DOX-Day2 and 
DOX-Day2WO groups compared to the Control-Day2 and 
Control-Day14 cardiomyocytes, respectively. Additionally, 
no significant increase in LDH leakage was observed after 
2 days of exposure to DOX at a concentration of 156 nM 
compared to controls (Fig. 3b). However, exposure to DOX 
at a concentration above 156 nM resulted in progressive 
increase in LDH release, which indicated the presence of 
cell membrane damage and cytotoxicity. These findings 
demonstrate that a 2-day exposure of DOX at 156 nM to 
cardiomyocytes could be used to identify early changes 
in miRNA expression levels under less-adverse cytotoxic 
conditions.
miRNA profiling identified early DOX‑responsive 
and persistently deregulated miRNAs
The miRNA microarray data analysis resulted in the iden-
tification of several differentially expressed miRNAs in the 
DOX-treated and washout groups (Fig. 4a). A single expo-
sure (DOX-Day2) and a repeated exposure (DOX-Day6) 
to DOX perturbed, in total, 21 (15 up-regulated and seven 
down-regulated) and 79 (37 up-regulated and 42 down-reg-
ulated) miRNAs, respectively. The five up-regulated miR-
NAs in the DOX-Day2WO group and the 26 miRNAs (15 
up-regulated and 11 down-regulated) in the DOX-Day6WO 
group showed prolonged differential expression during 
drug washout. Differentially expressed miRNAs under 
different experimental conditions are provided in Supple-
mental Table S1. A Venn diagram analysis was performed 
for DOX-exposed and drug washout groups to identify 
commonly deregulated miRNAs. The analysis identified 
14 (10 up-regulated and four down-regulated) commonly 
deregulated miRNAs between the DOX-Day2 and DOX-
Day6 groups (Fig. 4b, c). These 14 deregulated miRNAs 
are indicative of an early response to DOX, and their fold 
change values are provided in Table 1. Among the DOX-
exposed and drug washout groups, five miRNAs showed 
persistent up-regulation (Fig. 4d, and their fold change 
values are provided in Table 1), while no commonly down-
regulated miRNAs were observed (Fig. 4e).
Fig. 4  a Number of differ-
entially expressed miRNAs 
in different experimental 
conditions. Three independent 
experiments were performed 
for miRNA microarray studies. 
Comparisons with respective 
control groups were performed 
to identify the DOX-induced 
differentially expressed 
miRNAs (with at least a fold 
change 1.8 and a p value <0.05 
vs. control). The number 
of up- and down-regulated 
miRNAs is presented in the 
bar graph. The miRNAs, those 
did not deregulate during DOX 
exposure but showed deregula-
tions during drug washout were 
omitted from washout groups 
before the data analysis. b, c 
Venn diagrams representing the 
number of commonly up- and 
down-regulated miRNAs among 
the DOX-Day2 and DOX-Day6 
groups, respectively. d, e Venn 
diagrams illustrating number 
of overlapping up- and down-
regulated miRNAs among the 
DOX-exposed and washout 
groups, respectively
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Verified miRNA‑gene targets enriched in cardiac 
and stress‑associated GOs
Verified gene targets of each miRNA in Table 1 were first 
identified using the miRWalk 2.0 bioinformatics tool. The 
putative gene targets of the up-regulated miRNAs were 
matched with the identified DOX-induced differentially 
down-regulated genes at day 2, 6 and 14 as previously 
described (Chaudhari et al. 2015) (see Supplemental Table 
S2). Common confirmed genes were analysed for the 
enrichment of GO and KEGG pathways using the DAVID 
functional enrichment programme. This analysis revealed 
early DOX-affected cardiac processes, pathways and gen-
eral toxic responses (Table 2). The down-regulated genes 
were mainly enriched for GO terms such as the sarcomere, 
muscle contraction and ion channel activity, and KEGG 
pathways such as cardiac muscle contraction, HCM, DCM 
and the MAPK signalling pathway. The putative target 
genes of the down-regulated miRNAs were matched with 
the up-regulated genes. Analysis of the common verified 
genes revealed enrichment for GO terms such as apoptosis, 
oxidative stress, inflammatory responses and the extracel-
lular region (Table 2). Other GOs are provided in Supple-
mental Table S3. Verified gene targets of miR-187-3p, miR-
486-5p, miR-34a, miR-212-3p, miR-34c-3p, miR-675-5p 
and miR-3911 were not enriched for GO terms related to 
cardiac and general toxicity responses. Similarly, verified 
gene targets of persistently up-regulated miRNAs were not 
enriched for cardiac-related GOs.
Validation of deregulated miRNA expression using 
qPCR
The 14 early DOX-responsive miRNAs and the five per-
sistently up-regulated miRNAs were validated using qPCR 
(for primers sequences see supplemental Table S4). The 
qPCR data analysis confirmed deregulation of nine miR-
NAs (8 up and 1 down) in both DOX-Day2 and DOX-Day6 
groups (Fig. 5a, b), and also confirmed the prolonged up-
regulation of three miRNAs in the washout groups at day 
14 (Fig. 5c).
Discussion
High throughput miRNA profiling is progressively becom-
ing an important screening tool to identify miRNAs that are 
responsive to drugs and environmental factors. Using this 
approach, in the present study, we identified early and pro-
longed DOX deregulated miRNAs that can be used to detect 
cardiotoxicants. Myocardial apoptosis is one of the main 
causes of progressive heart failure during DOX treatment. 
In the present study, repeated exposure to 156 nM DOX-
induced substantial cytotoxicity in the DOX-Day6 group, 
which resulted in cell death and loss of cardiomyocytes. 
In addition, we also found that compared to controls and 
a single-DOX exposure group, hiPSC-CMs after repeated 
exposure to DOX showed arrhythmic beating (Chaudhari 
et al. 2015). Previous reports have shown that DOX induces 
myocardial apoptosis in animal models (Fisher et al. 2005; 
Sharov et al. 1996; Ueno et al. 2006). Increasing evidence 
suggests that apoptosis is crucially involved in the loss of 
cardiomyocytes in failing human hearts (Olivetti et al. 
1997), myocarditis (Kawano et al. 1994) and myocardial 
infarction (Saraste et al. 1997). Ageing is also associated 
with a gradual decrease in cardiac performance and a loss 
of cardiomyocytes through apoptosis (Kwak 2013).
In this study, a miRNA microarray analysis revealed 14 
early DOX-responsive miRNAs. Of these 14 miRNAs, nine 
returned to basal levels during drug washout, whereas the 
other five miRNAs showed persistent up-regulation during 
drug washout. These results suggest that the effect of DOX 
on the expression of the majority of miRNAs in cardio-
myocytes is reversible if cardiomyocytes are only acutely 
exposed to DOX.
Validation of miRNA microarray data using qPCR con-
firmed deregulation of miR-187-3p, miR-182-5p, miR-
486-3p, miR-486-5p, miR-34a-3p, miR-4423-3p, miR-
34c-3p, miR-34c-5p and miR-1303 in both DOX-Day2 and 
DOX-Day6 groups. qPCR also confirmed the prolonged up-
regulation of miR-182-5p, miR-4423-3p and miR-34c-5p 
in DOX-Day2WO and DOX-Day6WO groups. These 
identified deregulated miRNAs showed an early response 
Table 1  Early and/or persistently deregulated miRNAs by DOX in 
hiPSC-CMs
The fold change values were obtained using miRNA microarray data 
analysis (n = 3, p value <0.05 vs. control)




miR-187-3p 20.7 66.6 14.1 33.6
miR-182-5p 10.9 16.9 3.0 10.2
miR-486-5p 5.4 3.6 2.1 2.8
miR-34a-3p 5.2 10.1 – 2.8
miR-486-3p 3.8 6.8 – 2.3
miR-212-3p 2.5 2.5 – –
miR-
4423-3p
2.3 7.2 2.35 4.0
miR-139-5p 2.0 1.9 – –
miR-34c-3p 1.9 2.0 – 2.1
miR-34c-5p 1.8 4.5 2.22 2.3
miR-3911 −3.5 −3.7 – –
miR-675-5p −3.5 −9.2 – −2.4
miR-4298 −2.0 −2.5 – –
miR-1303 −1.8 −3.5 – –
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to DOX that occurred before the induction of general cyto-
toxic biomarkers such as LDH. A 156 nM DOX treatment 
for 24 and 48 h did not induce a significant release of car-
diac troponin T (cTnT) from hESC-derived cardiomyocytes 
in culture medium (Andersson et al. 2010; Holmgren et al. 
2015). These observations indicate that miRNAs appear to 
be more sensitive toxicity signatures compared to LDH and 
other biomarkers such as cardiac troponin in DOX-exposed 
hiPSC-CMs. qPCR validated the use of the identified miR-
NAs in further investigations.
Table 2  Significantly enriched GOs of verified gene targets of early DOX-responsive miRNAs
The data show a significant enrichment of cardiac-related GOs and pathways for upregulated miRNAs, specifically, miR-182-5p, miR-486-3p, 
miR-4423-3p, miR-139-3p and miR-34c-5p, while down-regulated miRNAs, such as miR-1303 and miR-4298, were enriched for GOs related to 
stress and apoptosis
Category Term Count p value Downregulated genes
miR-182-5p
 KEGG_PATHWAY hsa04260:Cardiac muscle contraction 3 1.60E−02 COX6A2, ATP1A2, MYH6
miR-486-3p
 GOTERM_CC_FAT GO:0030017~sarcomere 4 3.00E−03 DES, LDB3, FHL2, MYH7
 GOTERM_BP_FAT GO:0006936~muscle contraction 4 1.90E−02 DES, MYH7, SCN5A, SGCA
 KEGG_PATHWAY hsa05410:Hypertrophic cardiomyopathy 
(HCM)
3 3.20E−02 DES, MYH7, SGCA
 GOTERM_BP_FAT GO:0008016~regulation of heart contrac-
tion
3 3.30E−02 DES, MYH7, SCN5A
 KEGG_PATHWAY hsa05414:Dilated cardiomyopathy (DCM) 3 3.70E−02 DES, MYH7, SGCA
 GOTERM_MF_FAT GO:0005216~ion channel activity 5 4.70E−02 KCNN2, ANO4, SCN5A, FXYD6, KCNK3
miR-4423-3p
 KEGG_PATHWAY hsa04260:Cardiac muscle contraction 3 1.20E−02 MYL3, ATP1B4, CACNA2D2
 GOTERM_CC_FAT GO:0014704~intercalated disc 2 3.00E−02 NRAP, CTNNA3
 GOTERM_BP_FAT GO:0007507~heart development 3 4.70E−02 MYL3, FGF12, GJA5
miR-139-3p
 GOTERM_CC_FAT GO:0030017~sarcomere 4 2.20E−03 ANK2, DMD, LDB3, MYH7
 GOTERM_MF_FAT GO:0008307~structural constituent of 
muscle
3 4.20E−03 DMD, MYH7, ASPH
 GOTERM_CC_FAT GO:0005856~cytoskeleton 9 2.60E−02 MAD2L1, ANK2, SPAG5, DMD, LDB3, KIF18A, 
CENPE, MYH7, TOP2A
miR-34c-5p
 KEGG_PATHWAY hsa04010:MAPK signalling pathway 5 8.20E−03 IL1R1, RASGRP2, FGF12, CACNA2D2, MYC
 GOTERM_BP_FAT GO:0006936~muscle contraction 4 1.30E−02 MYOM2, ARG2, MYH6, SCN5A
 GOTERM_CC_FAT GO:0030017~sarcomere 3 3.40E−02 ANK2, FHL2, MYH6








GO:0044421~extracellular region part 12 3.10E−04 PROM1, A2M, THBD, MASP1, SULF2, 




GO:0042981~regulation of apoptosis 8 2.50E−02 DHRS2, EI24, BDNF, TNFRSF10B, 
TNFRSF10D, NRG1, GSTP1, TP53INP1
 GOTERM_BP_
FAT
GO:0050727~regulation of inflammatory 
response
3 3.10E−02 A2M, MASP1, ACE2
 GOTERM_BP_
FAT
GO:0006916~anti-apoptosis 4 3.80E−02 BDNF, TNFRSF10D, NRG1, GSTP1
 GOTERM_BP_
FAT
GO:0002526~acute inflammatory response 3 4.90E−02 A2M, MASP1, TRPV1
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The miR-34 family members are involved in cardiac 
ageing, cardiac diseases and in cardiac apoptotic events. 
Recently, significant up-regulation of miR-34a has been 
reported in the aged hearts of mice (Boon et al. 2013), after 
myocardial infarction in mice (Lin et al. 2010) and after 
human dilated cardiomyopathy (Elzenaar et al. 2013). This 
up-regulation of miR-34a is associated with a loss of car-
diomyocytes via apoptosis in both myocardial infarction 
patients and rats (Fan et al. 2013). Higher plasma levels of 
miR-34a may be a predictive indicator of heart failure after 
acute myocardial infarction in patients (Matsumoto et al. 
2013) and may be a potential biomarker for coronary artery 
disease (Han et al. 2015). DOX-induced up-regulation of 
miR-34a has been reported recently in a mouse model (Desai 
et al. 2014). In agreement with these observations, our 
results show that DOX-induced up-regulation of miR-34a-3p 
expression can be correlated with increased apoptosis and 
decreased cell viability in repeatedly exposed cardiomyo-
cytes (DOX-Day6). These results suggest a potential role of 
miR-34a-3p in early cytotoxic events in hiPSC-CMs.
Similarly, miR-34b and miR-34c (miR-34 family mem-
bers) are up-regulated during rat cardiac hypertrophy (Feng 
et al. 2014), in the aged hearts of mice (Boon et al. 2013), 
in mouse hearts with myocardial infarction (Bernardo et al. 
2012) and in diabetic ischaemic heart failure patients (Greco 
et al. 2012). DOX-induced up-regulation of miR-34b and 
miR-34c was reported in a mouse model (Desai et al. 2014) 
and in rat hearts (Vacchi-Suzzi et al. 2012). Consistent with 
these observations, our data demonstrated early up-regulation 
of miR-34c-3p and miR-34c-5p during DOX exposure. Fur-
thermore, miR-34c-5p showed persistent up-regulation after 
the drug washout. Enriched GOs of verified gene targets of 
miR-34c-5p included those such as the sarcomere and muscle 
contraction and verified down-regulated gene targets includ-
ing ion channels such as KCNN2, SCN5A, CACNA2D2 and 
KCNK3. As previously shown, these findings can be linked to 
arrhythmic beating in cardiomyocytes during repeated expo-
sure to DOX (Chaudhari et al. 2015). These observations sug-
gest that up-regulation of miR-34c-3p and miR-34c-5p may 
be early indicators of cardiac dysfunction, the development of 
cardiac pathologies and future heart failure.
A higher expression level of miR-486-3p has been found 
in cats with hypertrophic cardiomyopathy (Weber et al. 
2015) and in humans with DCM and HCM (Leptidis et al. 
2013). Consistent with these reports, our present study 
shows an up-regulation of miR-486-3p in DOX-exposed car-
diomyocytes. Additionally, the enriched GOs of the verified 
gene targets of miR-486-3p included those related to car-
diac contractile function and ion channel activity. Also, the 
enriched KEGG pathways included HCM and DCM. Early 
up-regulation of miR-486-3p could lead to impaired cardiac 
function, and possibly to cardiomyopathies in hiPSC-CMs.
Fig. 5  Quantitative real-time 
PCR (qPCR) validation of 
miRNA microarray data. The 
qPCR confirmed significant a 
up-regulation of eight miRNAs, 
b down-regulation of miR-
1303 in both the DOX-Day2 
and DOX-Day6 groups, and 
c prolonged up-regulation of 
miR-182-5p, miR-4423-3p and 
miR-34c-5p in the drug washout 
groups at day 14. The bar graph 
represents the fold regulation of 
miRNAs as the mean ± stand-
ard deviation (n = 3, p value 
<0.05 vs. control)
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miR-486 is one of the highly enriched miRNA species in 
human and mouse hearts (Alexander et al. 2014). Overexpres-
sion of miR-486 reduces PTEN levels and activates PI3K/
AKT signalling, which eventually leads to cardiac hypertro-
phy (Small et al. 2010b). Increased expression of miR-486-5p 
has been found in the plasma of acute myocardial infarction 
patients (Hsu et al. 2014) and also in cats with hypertrophic 
cardiomyopathy (Weber et al. 2015). Our findings showing a 
DOX-induced early up-regulation of miR-486-5p suggest that 
elevation of miR-486-5p may be considered as an early event 
in the development of cardiovascular diseases.
Among early up-regulated miRNAs, miR-187-3p showed 
the highest up-regulation in our miRNA microarray data 
analysis. Until now, no reports of miR-187-3p in heart fail-
ure and DOX-mediated cardiotoxicity have been observed. 
For the first time, we demonstrated that DOX caused a 
higher expression of miR-187-3p in human cardiomyocytes. 
Notably, miR-187-3p overexpressing T-lymphoma cells 
show resistance to DNA damaging agents such as DOX, 
cisplatin and cyclophosphamide (Yan et al. 2014). Thus, we 
may assume that miR-187-3p overexpression in cardiomyo-
cytes is the result of DOX-induced DNA damage. However, 
more studies are needed to unveil the role of miR-187-3p in 
both cardiotoxicity and the development of heart failure.
An elevated level of miR-182 was found in patients with 
coronary disease (Taurino et al. 2010), dilated cardiomyo-
pathy and chronic congestive heart failure (Zhu et al. 2013). 
DOX-induced DNA damage is an early event of lethal car-
diac injury and cell death (L’Ecuyer et al. 2006). Moreover, 
increased levels of miR-182 impede the DNA repair pro-
cess and increase genomic instability in cancer cell lines 
(Krishnan et al. 2013; Moskwa et al. 2011; Yao and Ventura 
2011). Additionally, increased expression of miR-182 in 
melanoma cells after DOX treatment has been reported 
(Yan et al. 2012). Similarly, in our study, DOX induced the 
up-regulation of miR-182-5p in hiPSC-CMs, while veri-
fied gene targets enriched KEGG pathways such as cardiac 
muscle contraction. These observations suggest that miR-
182-5p may be an initial indicator of cardiac injury and 
possibly DNA damage. The prolonged up-regulation of this 
miRNA may explain the mechanism of DOX-induced car-
diac diseases and heart failure.
In the present study, we found that DOX induced an 
early and prolonged up-regulation of miR-4423-3p in 
hiPSC-CMs. Verified gene targets of miR-4423-3p were 
significantly enriched in both cardiac-specific GOs and 
KEGG pathways such as cardiac muscle contraction. 
Further investigation is needed to understand role of this 
miRNA in early cardiac damage, and more generally, in 
the progressive development of cardiac diseases. Our study 
also showed down-regulation of miRNAs particularly miR-
1303 and miR-4298 after DOX exposure. In addition GO 
enrichment analysis showed that verified gene targets of 
miR-1303 and miR-4298 significantly enriched GOs asso-
ciated with stress and apoptosis. However, role of these two 
miRNAs in development of cardiac pathogenesis or heart 
failure or ageing needs an in-depth investigation.
As we previously described (Chaudhari et al. 2015), a 
single exposure of 156 nM DOX compromised the beat-
ing heart rate without inducing cytotoxicity. In addition, 
a 156 nM concentration of DOX is within the therapeu-
tic range of DOX. Repeated exposure to DOX (156 nM) 
induced substantial cytotoxicity in hiPSC-CMs. The nine 
validated miRNAs were significantly deregulated with 
a single exposure to DOX before the indication of the 
cytotoxicity marker LDH. In the present study, an early 
up-regulation of miR-34 family members was identi-
fied, which indicated that apoptosis could be a very early 
molecular event that induces cardiac cell loss in hiPSC-
CMs after repeated exposure to DOX. Other early up-reg-
ulated miRNAs suggest a possible risk of cardiovascular 
diseases, such as cardiac hypertrophy and future heart 
failure. Prolonged up-regulation of three miRNAs sug-
gests a risk of cardiac pathophysiology during the long-
term recovery phase of DOX-exposed hiPSC-CMs. The 
DOX-induced miRNA deregulation in hiPSC-CMs is an 
indicative of complex molecular changes related to apop-
tosis, ageing, senescence, hypertrophy and other cardiac 
diseases, which ultimately progress towards cardiac dys-
function and heart failure. The early-deregulated miRNAs 
identified in this study might be beneficial for the iden-
tification and development of early genomic biomarkers 
of cardiotoxicity in humans and may also be useful for 
evaluating the risk of cardiac damage caused by potential 
therapeutic drugs and/or environmental factors with simi-
lar mechanism of action.
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